Hyperthermia Blog

News and Opinions About Our Industry

One of our goals at Pyrexar Medical is to connect and share all of the great advancements in hyperthermia from around the world. We believe that access to information, sharing of data and participating in a global effort can give access to hyperthermia to more people.

We have started a new section on our website called Opinion Leaders.  The purpose of this section is to initiate conversation and make new connections among physicians and researchers currently in the field.  We want to create a community for those centers who want to add hyperthermia to their standard of care. We also believe this may give researchers an accelerated path to clinical studies by offering a larger patient database.

New Opinion Leaders section onthe Pyrexar Medical Website

Current hyperthermia-focused conferences are in place but often lack the critical mass to expand hyperthermia centers in a meaningful way.  There also lacks the global data sharing necessary to move phase III studies forward.  For example, the Hyperthermia European Adjuvant Trial (HEAT) is a randomized clinical phase III study comparing chemotherapy vs chemotherapy plus hyperthermia in the treatment of pancreatic cancer.  Initiated in 2012 and with an estimated enrollment of 336 participants, the study hopes to fully populate sometime this year.  Seven years to generate a viable population study and another two years of data analysis.  Could future studies move more rapidly if we had a global collaboration?

We hope we can advance this concept in the near future.  Today, we want you to meet Dr. Nagraj Huilgol, our first entry in our Opinion Leaders directory.

We just returned from a trip to India to attend the SCRAC (Society of Cancer Research and Communication) meeting in the coastal town of Juhu, Mumbai, India.  We had the opportunity to meet radiation oncologists and cancer specialists from the region, and to present our pitch for hyperthermia. We have received positive indications that there will be several Pyrexar Medical Hyperthermia suites installed in India in 2019.

India is projected to be the world's most populous country by 2024.  Surpassing the population of China,  it is expected to be home to more than 1.7 billion people by 2050.  With this continuing growth, the demand for health services also grows. The opportunities in the country are vast and it appears hyperthermia has a chance to gain a foothold as a valuable adjunct cancer treatment.

SCRAC 2019 Program

Introduction to MRI Imaging - Dr. Mitusha Verma; Nanavati Hospital
Texture analysis - a novel technique in Radio-genomics - Dr. Balaji Ganeshan; Chief Executive Officer TexRAD Ltd UK
Introduction to MRI with Hyperthermia - Mr. Mark Falkowski, CEO; Pyrexar Medical
MRI to study heat induced changes for diagnostics and MRTI - Dr. Nagraj Huilgol; Nanavati Hospital
Group discussion to explore the possibilities to harness heat for diagnostics.

 

 

Last month the local affiliate in Salt Lake City, UT (headquarters for Pyrexar Medical) aired a five-part series on the use of hyperthermia in the treatment of cancer. The report focused on one of our customer sites, Gamma West Cancer Services, and their use of interstitial hyperthermia in combination with brachytherapy.

Key points from this series

  • Hyperthermia is a safe and highly effective cancer treatment
  • Several patients featured in the story had no expectation of survival before hyperthermia
  • Excellent adjunct treatment for Brachytherapy with similar treatment planning
 

We have added English language captions to the video series. This is an excellent opportunity to share this life-saving information on your social media websites. The more individuals that learn about this treatment, the more lives we can change.

Visit the Pyrexar Medical YouTube Channel or use the links below.

A friendly reminder that the main Hyperthermia Conference Events in the US and Europe are right around the corner. These conferences are a gathering of the best in hyperthermia research and an excellent resource for those interested in the field of thermal oncology.

STM ESHO 2019

The 36th Annual Meeting of the Society for Thermal Medicine and the 33rd Annual Meeting of the European Society for Hyperthermic Oncology will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding of thermal medicine in the context of engineering, physics, materials science, and biology.

Keynote and Plenary speakers will highlight the extensive connections between physics, information science, biology, imaging, and the thermal state.

New: Clinical Hyperthermia Training Added to STM

  • How to establish a hyperthermia program
  • Practice guidelines for superficial hyperthermia
  • Practice guidelines for deep hyperthermia
  • Practice guidelines for interstitial hyperthermia
  • Equipment, planning, and execution of MW superficial hyperthermia treatment
  • Equipment, planning, and execution of RF deep hyperthermia treatment
  • Assessment of hyperthermia treatments based on hypoxia imaging
  • Clinical workflow, documentation and reimbursement of hyperthermia treatments
  • Impact of hyperthermia referrals in a Radiation Oncology Department

Who Should Attend?

  • Researchers in the field of thermal oncology
  • Clinicians, new to the field, who would like to talk with experts
  • Clinicians who want to expand their thermal oncology program
  • Medical Students that want to understand how hyperthermia may impact the future of medicine.
  • Pyrexar Distributors who want to expand their working knowledge of hyperthermia
  • Potential purchasers of hyperthermia equipment

Here are some dates to help you plan

  STM ESHO
Conference Dates: Apr 28 - May 2 May 22-24
Location: St. Pete's Beach, Florida Warsaw, Poland
Venue: Tradewinds Grand Island Resort Warsaw Plaza Hotel
Conference Pass: $650 - $1300 € 250 - €400
Hyperthermia Workshop/Training $75 € 35 - €65
Hotel: $255 - $345 €149 - €218
Show Website: